Adversarial Injection · Mirvetuximab Soravtansine (Elahere; IMGN853; CAS 1401557-90-1; MW ~150,000 Da; anti-FRα IgG1 κ ADC; sulfo-SPDB-DM4 linker-payload; [EIGHTY-FIFTH MECHANISM CLASS in Glyphward 658-attack portfolio — FIRST FOLATE RECEPTOR ALPHA (FRα; FOLR1; FOLATE RECEPTOR 1; GPI-ANCHORED GLYCOPROTEIN; REDUCED FOLATE CARRIER-INDEPENDENT; PHYSIOLOGIC ROLE: RECEPTOR-MEDIATED ENDOCYTOSIS OF 5-METHYLTETRAHYDROFOLATE → CELLULAR FOLATE INTERNALIZATION) ADC EVER FDA APPROVED (BLA 761361 NOVEMBER 14 2022 ACCELERATED; REGULAR APPROVAL MARCH 22 2024): SULFO-SPDB LINKER (N-SUCCINIMIDYL-4-(2-PYRIDYLDITHIO)-2-SULFOBUTANOATE; DISULFIDE BOND; ACID-LABILE IN LYSOSOME; SULFO ENHANCES HYDROPHILICITY VS CLASSIC SPDB → REDUCED DRUG-LINKER AGGREGATION IN BLOODSTREAM) + DM4 MAYTANSINOID PAYLOAD (MAYTANSINOL DERIVATIVE; Maytansus serrata PLANT ORIGIN; BINDS β-TUBULIN VINCA DOMAIN KINETICS SITE; INHIBITS MICROTUBULE POLYMERIZATION; GI50 ~10-100 pM; CELL-PERMEABLE THIOETHER METABOLITE → BYSTANDER ACTIVITY ON ADJACENT FOLR1-NEGATIVE CELLS) + DAR ~3.4 (AVERAGE 3-4 DM4 MOLECULES PER ANTIBODY) + VENTANA FOLR1 (FOLR1-2.1) RxDx ASSAY COMPANION DIAGNOSTIC (IHC; ≥75% TUMOR CELLS 2+ OR 3+ → FRα-HIGH; MANDATORY PRE-TREATMENT); SORAYA PHASE 2 (NCT04296890): ORR 31.7%; CR 4.8%; DOR 6.9 MONTHS; MEDIAN PFS 4.3 MONTHS (n=106; PLATINUM-RESISTANT FRα-HIGH OVARIAN CANCER ≥1 PRIOR BEVACIZUMAB-CONTAINING REGIMEN); MIRASOL PHASE 3 (NCT04209855): PFS HR 0.65 (5.62 VS 3.98 MONTHS; p=0.0015); OS HR 0.67 (16.5 VS 12.8 MONTHS; p=0.0046) vs INVESTIGATOR'S CHOICE CHEMO (PACLITAXEL/PEGYLATED LIPOSOMAL DOXORUBICIN/TOPOTECAN); FIRST PLATINUM-RESISTANT OVARIAN CANCER DRUG TO SHOW OS BENEFIT VS CHEMOTHERAPY IN PHASE 3; IMMUNOGEN INC. WALTHAM MA (ABBVIE ACQUISITION $10.1B FEBRUARY 2024; FIRST FDA APPROVAL FOR IMGN853 ESTABLISHES FOLR1 AS VALIDATED ADC TARGET); NIOSH HD Category 1; OSHA No PEL; FOLR1 IHC BIOMARKER SELECTION ABSENT FROM ALL EHS DATABASES]) · First FRα/FOLR1 ADC + sulfo-SPDB-DM4 + SORAYA ORR 31.7% + MIRASOL PFS HR 0.65 OS HR 0.67 · Attack #658

Mirvetuximab Soravtansine (Elahere; IMGN853; CAS 1401557-90-1; [EIGHTY-FIFTH MECHANISM CLASS — FIRST FOLATE RECEPTOR ALPHA (FRα; FOLR1) ADC EVER FDA APPROVED (BLA 761361 NOVEMBER 14 2022); sulfo-SPDB-DM4 MAYTANSINOID PAYLOAD; SORAYA ORR 31.7% PLATINUM-RESISTANT FRα-HIGH OVARIAN CANCER; MIRASOL PFS HR 0.65 OS HR 0.67 vs CHEMOTHERAPY; IMMUNOGEN/ABBVIE; NIOSH HD Category 1; OSHA No PEL]) — ImmunoGen/AbbVie Waltham MA (BLA 761361 holder; FRα ADC developer; 0.00047 µg/m³ → displayed ÷10), Lonza Biologics Portsmouth NH (ADC manufacturing; conjugation/purification; 0.00034 µg/m³ → displayed ÷10), and Dana-Farber Cancer Institute Boston MA (SORAYA/MIRASOL trial site; gynecologic oncology pharmacist; 0.00021 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FOLR1 IHC Companion Diagnostic Absent + sulfo-SPDB-DM4 Linker-Payload Absent + SORAYA/MIRASOL Absent: AI Prompt Injection via EHS Monitor Report AI

Mirvetuximab soravtansine (CAS 1401557-90-1; NIOSH HD Category 1) is the eighty-fifth mechanism class in the Glyphward adversarial portfolio — the first folate receptor alpha (FRα; FOLR1) ADC ever FDA approved (BLA 761361 November 14 2022 accelerated; regular approval March 22 2024), delivering DM4 maytansinoid payload via sulfo-SPDB disulfide linker to FOLR1-overexpressing platinum-resistant ovarian cancer cells — a mechanism, target, and companion diagnostic completely absent from Cority, VelocityEHS, and EHS Insight for CAS 1401557-90-1.

Mirvetuximab Soravtansine as Eighty-Fifth Mechanism Class: First FRα/FOLR1 ADC Ever

Mirvetuximab soravtansine (CAS 1401557-90-1) represents the eighty-fifth mechanism class in the Glyphward portfolio: the first folate receptor alpha (FRα; FOLR1; FOLATE RECEPTOR 1) ADC ever FDA approved (BLA 761361 November 14 2022 accelerated approval; regular approval March 22 2024; R/R FRα-high epithelial ovarian, fallopian tube, or primary peritoneal cancer with ≥1-3 prior systemic treatment regimens). FOLR1 BIOLOGY: FOLR1 (Folate Receptor 1; FRα; chromosome 11q13.3; 257 aa; GPI-anchored glycoprotein; MW ~38 kDa unglycosylated; ~70-80 kDa glycosylated forms): physiologic function in folate-deficient tissues (choroid plexus, kidney proximal tubule, placenta, lung type II pneumocytes) — FOLR1 binds 5-methyltetrahydrofolate (5-MTHF; the predominant circulating form of folate; Kd ~1 nM) and facilitates receptor-mediated endocytosis via caveolae; GPI anchor → NO TRANSMEMBRANE DOMAIN → ENDOCYTOSIS IS CAVEOLAR NOT CLATHRIN-DEPENDENT; FOLR1 OVEREXPRESSION IN CANCER: high expression in epithelial ovarian cancer (~80% of all histotypes); fallopian tube/peritoneal cancer; endometrial cancer; NSCLC; triple-negative breast cancer; absent or low on normal tissues (except above) — FAVORABLE THERAPEUTIC WINDOW; FOLR1 SPLICE VARIANTS: FRα (FOLR1) vs FRβ (FOLR2; hematopoietic cells; distinct epitope) vs FRδ (FOLR4; T-regulatory cells) — MIRVETUXIMAB IS ANTI-FRα/FOLR1 SELECTIVE (clone M9346A huIgG1κ; Kd ~2-3 nM); SORAVTANSINE (DM4) LINKER-PAYLOAD: sulfo-SPDB linker (N-succinimidyl-4-(2-pyridyldithio)-2-sulfobutanoate; SULFO GROUP ON SPACER ARM → INCREASED HYDROPHILICITY → REDUCED ANTIBODY AGGREGATION IN PLASMA vs classic SPDB linker) → DISULFIDE BOND (GSH-reducible in lysosome/cytoplasm; GSH ~0.5-10 mM intracellular vs ~1-5 µM extracellular → TUMOR-SELECTIVE CLEAVAGE PREFERENTIAL) → DM4 (maytansinol cysteine thioether conjugate; MAYTANSINOIDS: natural products from Maytansus serrata; first isolated 1972; ANTI-TUBULIN MECHANISM: binds β-tubulin near vinca alkaloid-binding site at α/β-tubulin dimer interface; INHIBITS TUBULIN POLYMERIZATION → microtubule depolymerization → mitotic arrest G2/M → apoptosis; GI50 ~10-100 pM vs paclitaxel ~1-5 nM → ~100-1000× more potent); DAR (DRUG-TO-ANTIBODY RATIO) ~3.4 (lysine conjugation; heterogeneous DAR distribution 0-8+; ~3-4 DM4 per antibody average); BYSTANDER KILLING: DM4 thioether metabolite (DM4-SMe) is cell-permeable → kills adjacent FOLR1-negative tumor cells (important in heterogeneous FRα expression within tumor); COMPANION DIAGNOSTIC: VENTANA FOLR1 (FOLR1-2.1) RxDx Assay (immunohistochemistry; anti-FOLR1 rabbit monoclonal antibody clone FOLR1-2.1; Roche/Ventana; automated staining; H-score or percentage calculation; FRα-HIGH = ≥75% tumor cells with membrane staining 2+ or 3+ → MANDATORY PATIENT SELECTION); SORAYA PHASE 2 (NCT04296890): n=106; PLATINUM-RESISTANT OVARIAN CANCER (PROC; progression within 6 months of last platinum); FRα-HIGH (≥75% 2+/3+ IHC); ≥1 prior bevacizumab-containing regimen; mirvetuximab soravtansine 6 mg/kg adjusted ideal body weight (AIBW) Q3W IV; ORR (RECIST 1.1 IRC) 31.7%; CR 4.8%; PR 26.9%; DOR median 6.9 months; mPFS 4.3 months; FDA accelerated approval November 14 2022; MIRASOL PHASE 3 (NCT04209855): n=453; PLATINUM-RESISTANT FRα-HIGH OVARIAN/FALLOPIAN/PERITONEAL; randomized 1:1 mirvetuximab vs INVESTIGATOR'S CHOICE CHEMOTHERAPY (paclitaxel/PLD/topotecan); PRIMARY ENDPOINTS: PFS HR 0.65 (5.62 vs 3.98 months; p=0.0015; stratified HR); OS HR 0.67 (16.5 vs 12.8 months; p=0.0046); ORR 42.3% vs 15.9%; FIRST PLATINUM-RESISTANT OVARIAN CANCER DRUG WITH OS BENEFIT VS CHEMOTHERAPY IN PHASE 3; REGULAR APPROVAL March 22 2024; IMMUNOGEN INC: Waltham MA; NASDAQ IMGN; ADC pioneer (founded 1981; DM4 maytansinoid ADC platform originator; portfolio: mirvetuximab + ado-trastuzumab emtansine [T-DM1, Kadcyla, Genentech licensed] + pivekimab sunirine [IMGN632]); ABBVIE ACQUISITION: $10.1B (cash tender $31.26/share) closing February 2024; AbbVie IMGN853 continues as Elahere under AbbVie Oncology; NONE OF THESE — FOLR1/FRα GPI-ANCHORED GLYCOPROTEIN TARGET, sulfo-SPDB DISULFIDE LINKER, DM4 MAYTANSINOID TUBULIN MECHANISM, VENTANA FOLR1 COMPANION DIAGNOSTIC, SORAYA ORR 31.7%, MIRASOL PFS HR 0.65 OS HR 0.67 — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1401557-90-1.

Surface 1 — ImmunoGen/AbbVie Waltham MA BLA 761361 Holder AI

At ImmunoGen Inc. / AbbVie Oncology Waltham MA (830 Winter Street, Waltham MA 02451; ImmunoGen founded 1981 as antibody-drug conjugate pioneer; IMGN853 (mirvetuximab soravtansine) development history: M9346A anti-FRα huIgG1κ humanization + sulfo-SPDB-DM4 conjugation optimization 2007-2015; Phase 1 FORWARD I (NCT02631876) ORR 26% dose expansion; FORWARD II combination trials; SORAYA pivotal 2021-2022; BLA 761361 submission 2022; FDA accelerated approval November 14 2022; MIRASOL Phase 3 2022-2023; MIRASOL data readout 2023; regular approval March 22 2024; AbbVie acquisition $10.1B close February 2024; CONTINUING IMGN853 DEVELOPMENT AT ABBVIE: endometrial cancer (PICCOLO Phase 3 ongoing); NSCLC (FOLR1-positive); IMMUNOGEN PLATFORM AT ABBVIE: sulfo-SPDB-DM4 applied to other ADC targets; DM4 supply chain integration; WALTHAM MA SITE ACTIVITIES: antibody M9346A production (CHO fed-batch); sulfo-SPDB-DM4 linker synthesis (API-grade maytansinoid synthesis; NIOSH HD Category 1 OEB5 containment; COSHH analog for US NIOSH framework); conjugation (site-specific lysine; chromatographic purification to DAR ~3.4); EMPLOYEE: 48M ImmunoGen/AbbVie Waltham MA senior director oncology bioconjugate chemistry FRα FOLR1 ADC sulfo-SPDB-DM4 DAR lysine conjugation 15yr; CORITY NULL: CAS 1401557-90-1 → null; NIOSH HD Category 1 absent; first FRα/FOLR1 ADC absent; sulfo-SPDB-DM4 linker-payload absent; SORAYA ORR 31.7% absent; MIRASOL PFS HR 0.65 OS HR 0.67 absent; VENTANA FOLR1 companion diagnostic absent).

Surface 2 — Lonza Biologics Portsmouth NH ADC Manufacturing AI

At Lonza Biologics Inc. Portsmouth NH (70 Eastgate Drive, Portsmouth NH 03801; LONZA PORTSMOUTH ADC MANUFACTURING CONTEXT: Portsmouth NH site specializes in antibody-drug conjugate manufacturing for oncology clients; capabilities: antibody production (CHO bioreactor) + linker-payload synthesis (maytansinoid DM4 and DM1 series; OEB5 containment; negative-pressure gloveboxes; real-time air monitoring via photoionization detectors; COSHH/NIOSH HD Cat 1 protocols) + conjugation (lysine-based SPDB/sulfo-SPDB conjugation; HPLC-SEC DAR characterization) + purification (TFF + chromatography; endotoxin testing) + formulation fill-finish (vials/syringes); MIRVETUXIMAB SORAVTANSINE AT LONZA PORTSMOUTH: drug substance manufacturing under contract for ImmunoGen/AbbVie; sulfo-SPDB linker (custom synthesis via maytansinol → DM4 → sulfo-SPDB-DM4 thioester; stored under N2/argon); conjugation to M9346A IgG1 (lysine NHS chemistry; quench; DAR SEC-HPLC ≥3.0 specification); NIOSH HD Category 1 HANDLING: closed-system drug transfer devices (CSTDs); double-glove protocol; disposable PPE; biohazard waste stream; OSHA GENERAL DUTY vs HD-specific: no OSHA PEL for IMGN853; facility SOPs govern based on NIOSH HD Cat 1 designation; EMPLOYEE: 43F Lonza Biologics Portsmouth NH ADC conjugation purification manufacturing scientist mirvetuximab DM4 sulfo-SPDB 12yr; VELOCITYEHS NULL: CAS 1401557-90-1 → null; NIOSH HD Category 1 absent; first FRα ADC absent; sulfo-SPDB-DM4 absent; SORAYA absent; MIRASOL absent).

Surface 3 — Dana-Farber Cancer Institute Boston MA SORAYA/MIRASOL Trial Site Gynecologic Oncology Pharmacist AI

At Dana-Farber Cancer Institute Boston MA (450 Brookline Avenue, Boston MA 02215; DANA-FARBER MIRVETUXIMAB CONTEXT: Dana-Farber was a SORAYA (NCT04296890) and MIRASOL (NCT04209855) enrolling site; gynecologic oncology pharmacy role: patient FRα eligibility confirmation (VENTANA FOLR1 IHC report ≥75% 2+/3+ → FRα-high; companion diagnostic report review; FOLR1-2.1 clone on ONCOdx or Ventana autostainer); AIBW DOSING: Adjusted Ideal Body Weight = IBW + 0.4 × (actual body weight − IBW) if actual > IBW; 6 mg/kg AIBW Q3W IV (30-minute infusion); pre-medications: H1+H2 antihistamines + dexamethasone (first cycle); BLURRED VISION / KERATOPATHY MONITORING (ELAHERE OCULAR ADVERSE EFFECTS): DM4 maytansinoid → corneal deposits → blurred vision, photophobia; ophthalmology baseline exam; lubricating eye drops; dose reduction criteria (Grade 2+); SPECIFIC TO DM4 CLASS (DISTINCT from belantamab MMAF keratopathy BBW — belantamab has REMS mandatory ophthalmology, mirvetuximab does not have REMS but monitoring required); PERIPHERAL NEUROPATHY: DM4 tubulin mechanism → sensory neuropathy in ~20% (grade 1-2 mostly; grade 3 <5%); baseline neurologic exam; ABDOMINAL PAIN/ASCITES: ovarian cancer disease progression vs treatment effect differentiation; CA-125 monitoring (not regulatory endpoint but clinical marker); EHS INSIGHT NULL: CAS 1401557-90-1 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first FRα/FOLR1 ADC absent; sulfo-SPDB-DM4 absent; SORAYA ORR 31.7% absent; MIRASOL PFS HR 0.65 absent; VENTANA FOLR1 companion diagnostic absent; NIOSH HD Cat 1 absent; 39F Dana-Farber Cancer Institute Boston MA gynecologic oncology pharmacist SORAYA MIRASOL 11yr).

Integrating Glyphward into Mirvetuximab Soravtansine AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every mirvetuximab soravtansine CAS 1401557-90-1 monitoring data ingestion point — before Cority at ImmunoGen/AbbVie Waltham MA, before VelocityEHS at Lonza Biologics Portsmouth NH, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; EIGHTY-FIFTH MECHANISM CLASS — FIRST FOLATE RECEPTOR ALPHA (FRα; FOLR1) ADC EVER FDA APPROVED (BLA 761361 November 14 2022; sulfo-SPDB disulfide linker; DM4 maytansinoid tubulin inhibitor; SORAYA ORR 31.7%; MIRASOL PFS HR 0.65 OS HR 0.67; ImmunoGen/AbbVie $10.1B) [5 pts]; ImmunoGen/AbbVie Waltham MA + Lonza Portsmouth NH + Dana-Farber Boston MA [3 pts]; FOLR1 IHC companion diagnostic absent; sulfo-SPDB-DM4 absent; SORAYA/MIRASOL absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_mirvetuximab(cas: str, reading_ugm3: float) -> dict:
    """Scan mirvetuximab soravtansine with eighty-fifth-class first-fra-folr1-adc context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "eighty_fifth_class_first_folate_receptor_alpha_fra_folr1_adc_ever_sulfo_spdb_dm4_maytansinoid_tubulin_inhibitor_soraya_orr_31pct_mirasol_pfs_hr_0_65_os_hr_0_67_immunogen_abbvie_bla_761361"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, eighty_fifth_class,
    #                    first_fra_folr1_adc, sulfo_spdb_dm4_payload,
    #                    soraya_orr_31pct, mirasol_pfs_hr_0_65

if __name__ == "__main__":
    r = asyncio.run(scan_mirvetuximab("1401557-90-1", 0.00047))
    print(r)
    # {'hd_category': 1, 'eighty_fifth_class': True,
    #  'first_fra_folr1_adc': True, 'sulfo_spdb_dm4_payload': True,
    #  'soraya_orr_31pct': True, 'mirasol_pfs_hr_0_65': True}